133153-76-1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1159016-02-0 C₄H₇N₃O₃ 
• 52558-24-4 (s)-3-tert-butoxycarbonylamino-2-hydroxypropionic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 186393-00-0 (S)-methyl 3-amino-2-hydroxypropanoate hydrochloride 

Downstream Products

• 1159016-08-6 methyl (S)-3-((tert-butoxycarbonyl)amino)-2-((tert-butyldiphenylsilyl)oxy)propanoate 
• 412352-66-0 (2S)‐3‐{[(tert‐butoxy)carbonyl]amino}‐2‐methoxypropanoic acid 
• 182571-08-0 methyl (R)-3-((tert-butoxycarbonyl)amino)-2-hydroxypropanoate 
• 1392222-60-4 (S)-3-((tert-butoxycarbonyl)amino)-2-((tert-butyldiphenylsilyl)oxy)propanoic acid 
• 1370458-18-6 C₄₀H₄₇BrCl₄N₈O₁₃ 
• 1370458-08-4 C₅₆H₆₅BrCl₄N₈O₁₃Si 
• 1370458-07-3 C₄₀H₄₇BrCl₄N₈O₁₃ 
• 1370458-06-2 C₅₆H₆₅BrCl₄N₈O₁₃Si 
• 1370458-05-1 Boc-Ise(TBDPS)-Trp(5-Br)-OH 
• 1370458-23-3 Boc-Ise(TBDPS)-Trp(5-Br)-OMe 

Relevant academic research and scientific papers

Tn Antigen Mimics by Ring-Opening of Chiral Cyclic Sulfamidates with Carbohydrate C1- S- and C1- O-Nucleophiles

Starting from commercially available (S)-isoserine and effectively accessible (S)-α-methylserine, enantiopure cyclic sulfamidates have been prepared as chiral building blocks for the synthesis of various S- and O-glycosylated amino acid derivatives, inclu

Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicines

The present invention relates to an amine compound for inhibiting SSAO/VAP-1 and application thereof in medicines. In particular, the present invention relates to an amine compound for inhibiting a semicarbazide-sensitive oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, or a pharmaceutically acceptable salt thereof, a stereoisomer or an/a E/Z isomer, further relates to a pharmaceutical composition containing the amine compound. The invention further relates to the application of the amine compound and the pharmaceutical composition in manufacture of the medicines for treatment of inflammation, inflammation-related diseases and immune diseases.

Application of the DP4 Probability Method to Flexible Cyclic Peptides with Multiple Independent Stereocenters: The True Structure of Cyclocinamide A

A DP4 protocol has been successfully utilized to establish the true structure of the natural product cyclocinamide A, a flexible cyclic peptide with four isolated stereocenters. Benchmarking the necessary level of theory required to successfully predict t

TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE

The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting RORγ activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.

Total synthesis of nominal (11S)- and (11R)-cyclocinamide A

The cyclocinamides possess a unique β2αβ 2α 14-membered tetrapeptide core. The initially reported biological data and intriguing structure, which was without full stereochemical identification, necessitated synthesis of both nominal (all-S) cyclocinamide A and the 11R isomer. The completed synthesis is highlighted by the use of a (cyclo)asparagine-containing dipeptide as a turn inducing fragment. Due to inconsistencies in analytical data between natural and synthetic samples, a re-evaluation of the natural product stereochemistry appears necessary.

A facile synthesis of 5,6-dihydro-5-hydroxy-2(1H)-pyridone

A short synthesis of 5,6-dihydro-5-hydroxy-2(1H)-pyridone was achieved from l-serine employing Horner-Emmons olefination as the key step.